Who are Clopidogrel + ASA + Bivalirudin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ticagrelor + ASA + Bivalirudin, Acetylsalicylic Acid + clopidogrel + acenocoumarol, Aspirin + Clopidogrel + Rivaroxaban.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clopidogrel-asa-bivalirudin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Clopidogrel + ASA + Bivalirudin — Competitive Intelligence Brief

Clopidogrel + ASA + Bivalirudin (Clopidogrel + ASA + Bivalirudin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent + Anticoagulant combination. Area: Cardiovascular.

marketed Antiplatelet agent + Anticoagulant combination P2Y12 receptor, cyclooxygenase, thrombin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Clopidogrel + ASA + Bivalirudin (Clopidogrel + ASA + Bivalirudin) — Juan J Badimon. This triple antiplatelet and anticoagulant combination inhibits platelet aggregation through multiple pathways while simultaneously blocking thrombin generation to prevent thrombotic events.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Clopidogrel + ASA + Bivalirudin TARGET	Clopidogrel + ASA + Bivalirudin	Juan J Badimon	marketed	Antiplatelet agent + Anticoagulant combination	P2Y12 receptor, cyclooxygenase, thrombin
Ticagrelor + ASA + Bivalirudin	Ticagrelor + ASA + Bivalirudin	Juan J Badimon	marketed	Antiplatelet agent + anticoagulant combination	P2Y12 receptor, COX-1, thrombin
Acetylsalicylic Acid + clopidogrel + acenocoumarol	Acetylsalicylic Acid + clopidogrel + acenocoumarol	Hospital Universitari Vall d'Hebron Research Institute	marketed	Antiplatelet agent + Anticoagulant combination	Platelet cyclooxygenase (COX), P2Y12 receptor, Vitamin K-dependent clotting factors
Aspirin + Clopidogrel + Rivaroxaban	Aspirin + Clopidogrel + Rivaroxaban	China National Center for Cardiovascular Diseases	marketed	Antiplatelet agent + Anticoagulant combination	Platelet cyclooxygenase, P2Y12 receptor, Factor Xa

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent + Anticoagulant combination class)

China National Center for Cardiovascular Diseases · 1 drug in this class
Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
Juan J Badimon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clopidogrel + ASA + Bivalirudin — Competitive Intelligence Brief. https://druglandscape.com/ci/clopidogrel-asa-bivalirudin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab